ADCs

Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD
GPCR & G Protein

5-HT Receptor Adenosine Receptor Adenylate Cyclase Adrenergic Receptor Angiotensin Receptor APJ Bombesin Receptor Bradykinin Receptor cAMP Cannabinoid Receptor CaSR CCK receptor CCR CGRP Receptor CRFR CXCR Dopamine Receptor EBI2 Endothelin Receptor Formyl Peptide Receptor Free Fatty Acid Receptor G protein-coupled Bile Acid Receptor GCGR GHSR GLP Receptor Glucagon Receptor GnRH Receptor GPCR19 GPR GPR109A Guanylate Cyclase Hedgehog(Smoothened) ROCK Histamine Receptor ICMT Leukotriene Receptor LPA Receptor LPL Receptor LTR mAChR Melanocortin Receptor Melatonin Receptor mGluR Motilin Receptor MRGPR MT Receptor Neurokinin Receptor Neuropeptide Y Receptor Neurotensin Receptor NPY receptor Opioid Receptor OX Receptor Oxytocin Receptor P2Y Receptor PAFR PAR PKD PKG Prostaglandin Receptor Ras RGS Protein S1P Receptor SGLT Sigma Receptor Somatostatin Receptor TAAR TSH Receptor Urotensin Receptor Vasopressin Receptor

+MORE

ADCs

ADCs related products

Cat No.	Product Name	CAS No.	Product Description
V79075	DepatuxizumabMMAE		Depatuxizumab MMAE is an antibody-active molecule conjugate (ADC) consisting of an anti-EGFR antibody (Depatuxizumab) and Monomethyl auristatin E (MMAE).
V52128	Enfortumabvedotin-ejfv	1346452-25-2	Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate used in urothelial cancer research.
V78751	Exatecan Intermediate 3		Exatecan Intermediate 3 is the intermediate of Exatecan.
V52099	Farletuzumab ecteribulin (MORAb-202)	2407465-18-1	Farletuzumab ecteribulin (MORAb-202) is an antibody-active molecule conjugate (ADC) consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab via reduced interchain disulfide bonds.
V76158	Izeltabart (IMGC-936)	2642078-60-0	Izeltabart (IMGC-936) is a Maytansinoid-based ADC targeting ADAM9.
V53069	KRAS degrader-1	2795275-59-9	KRAS degrader-1 (compound 1) is a potent KRAS degrader.
V41192	Mirvetuximab soravtansine (IMGN853)	1453084-37-1	Mirvetuximab soravtansine (IMGN853) is an antibody drug conjugate (ADC) consisting of the cytotoxic maytansoid DM4 covalently linked to humanized monoclonal antibody (mAb) M9346A.
V41040	Patritumab deruxtecan (HER3-DXd; U3-1287)	2227102-46-5	Patritumab deruxtecan (HER3-DXd) is an antibody-active molecule conjugate (ADC) consisting of the fully human anti-HER3 IgG1 monoclonal antibody (mAb) Patritumab linked to a topoisomerase via a tetrapeptide-based cleavable linker I Inhibitor payload composition [1].
V53244	Polatuzumab vedotin	1313206-42-6	Polatuzumab vedotin is an antibody-active molecular conjugate targeting CD79b.
V81404	SMP-33693		SMP-33693 is an Antibody-Drug Conjugates (ADCs) with a low payload shedding rate and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer.
V81405	SMP-88480		SMP-88480 is an Antibody-Drug Conjugates (ADCs).
V81406	SMP-93566		SMP-93566 is an Antibody-Drug Conjugates (ADCs) with a low payload shedding rate and has in vivo tumor suppressive effects on ovarian cancer, gastric cancer, and breast cancer.
V35270	Sofituzumab vedotin (DMUC5754A)	1418200-58-4	Sofituzumab vedotin (DMUC5754A) is an MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker.
V53089	Telisotuzumab vedotin (ABBV-399)	1714088-51-3	Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate (ADC) targeting c-Met.
V35170	Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine)	1642152-40-6	Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeted ADC that can be recognized and cleaved by cathepsin B in tumor cells, selectively targeting tumor cells.
V53255	Tusamitamab ravtansine (SAR-408701; HuMAb2-3-SPDB-DM4)	2254086-60-5	Tusamitamab ravtansine (SAR-408701) is a DM4 anti-CEACAM5 antibody-active molecule conjugate (ADC).
V81773	Zilovertamab vedotin (VLS-101; MK-2140)		Zilovertamab vedotin (VLS-101) is a novel antibody-active molecule conjugate (ADC) containing the humanized monoclonal antibody (mAb) zilovertamab and the anti-microtubule cytotoxic monomethyl vedotin.